Tag: tumor mutation burden
Tumor Mutation Burden: Evolution of a Controversial Biomarker From the Pathologist’s...
By Lynette M. Sholl, MD, and John W. Longshore, PhD, FACMG
Posted: February 12, 2020
The profound impact of immunotherapy in patients with lung cancer has...
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in...
By Neal Ready, MD, PhD
Posted: February 12, 2020
Programmed death receptor (PD-1) checkpoint monoclonal antibody therapy has proven a major advancement in the management of...
2019 IASLC World Conference on Lung Cancer Updates
Posted: November 12, 2019
More than 7,700 delegates from around the world attended the IASLC 2019 World Conference on Lung Cancer (WCLC). With sessions and...
